Yuichi Mikamoto

1.3k total citations · 1 hit paper
10 papers, 852 citations indexed

About

Yuichi Mikamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology. According to data from OpenAlex, Yuichi Mikamoto has authored 10 papers receiving a total of 852 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 2 papers in Gastroenterology. Recurrent topics in Yuichi Mikamoto's work include Cancer Immunotherapy and Biomarkers (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Yuichi Mikamoto is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Yuichi Mikamoto collaborates with scholars based in Japan. Yuichi Mikamoto's co-authors include Akihito Kawazoe, Shogo Nomura, Akihiro Sato, Masashi Wakabayashi, Kohei Shitara, Shota Fukuoka, Takeshi Kuwata, Hiroki Hara, Hiroyoshi Nishikawa and Yosuke Togashi and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Yuichi Mikamoto

10 papers receiving 843 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

2020 567 citations Shota Fukuoka, Hiroki Hara et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuichi Mikamoto Japan	7	688	318	219	196	147	10	852
Takako Yoshii Japan	8	579 0.8×	284 0.9×	195 0.9×	218 1.1×	110 0.7×	37	773
Hitomi Tamura Japan	6	553 0.8×	199 0.6×	188 0.9×	145 0.7×	109 0.7×	11	661
Nami Hirano Japan	7	535 0.8×	191 0.6×	178 0.8×	134 0.7×	104 0.7×	15	644
Salah-Eddin Al-Batran Germany	10	613 0.9×	441 1.4×	109 0.5×	256 1.3×	121 0.8×	30	828
S D'Emidio Italy	8	452 0.7×	267 0.8×	144 0.7×	265 1.4×	139 0.9×	14	781
Rita P. Dalal United States	10	415 0.6×	311 1.0×	88 0.4×	144 0.7×	109 0.7×	21	622
Akiko Kawano Nagatsuma Japan	12	381 0.6×	387 1.2×	101 0.5×	153 0.8×	57 0.4×	16	653
Fabiola Lorena Rojas Llimpe Italy	10	500 0.7×	498 1.6×	77 0.4×	217 1.1×	52 0.4×	32	791
Daniel Virgil Thomas Catenacci United States	11	365 0.5×	271 0.9×	106 0.5×	167 0.9×	42 0.3×	19	524
Guanghai Dai China	13	359 0.5×	354 1.1×	76 0.3×	183 0.9×	40 0.3×	34	670

Countries citing papers authored by Yuichi Mikamoto

Since Specialization

Citations

This map shows the geographic impact of Yuichi Mikamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichi Mikamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichi Mikamoto more than expected).

Fields of papers citing papers by Yuichi Mikamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichi Mikamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichi Mikamoto. The network helps show where Yuichi Mikamoto may publish in the future.

Co-authorship network of co-authors of Yuichi Mikamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichi Mikamoto. A scholar is included among the top collaborators of Yuichi Mikamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichi Mikamoto. Yuichi Mikamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Kotani, Daisuke, Hideaki Bando, Hiroya Taniguchi, et al.. (2024). Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).. Journal of Clinical Oncology. 42(16_suppl). 3585–3585. 1 indexed citations

2.

Shitara, Kohei, Hiroki Hara, Naoki Takahashi, et al.. (2020). Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).. Journal of Clinical Oncology. 38(4_suppl). 135–135. 9 indexed citations

3.

Hara, Hiroki, Akihito Kawazoe, Yasutoshi Kuboki, et al.. (2020). Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503).. Journal of Clinical Oncology. 38(4_suppl). 107–107. 4 indexed citations

4.

Kawazoe, Akihito, Shota Fukuoka, Yoshiaki Nakamura, et al.. (2020). Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. The Lancet Oncology. 21(8). 1057–1065. 184 indexed citations

5.

Kawazoe, Akihito, Shota Fukuoka, Yoshiaki Nakamura, et al.. (2020). An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).. Journal of Clinical Oncology. 38(4_suppl). 374–374. 5 indexed citations

6.

Fukuoka, Shota, Hiroki Hara, Naoki Takahashi, et al.. (2020). Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology. 38(18). 2053–2061. 567 indexed citations breakdown →

7.

Hara, Hiroki, Shota Fukuoka, Naoki Takahashi, et al.. (2019). Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Annals of Oncology. 30. iv124–iv124. 6 indexed citations

8.

Fukuoka, Shota, Hiroki Hara, Naoki Takahashi, et al.. (2019). Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).. Journal of Clinical Oncology. 37(15_suppl). 2522–2522. 59 indexed citations

9.

Kawazoe, Akihito, Yasutoshi Kuboki, Yoshito Komatsu, et al.. (2018). Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology. 36(15_suppl). 3530–3530. 10 indexed citations

10.

Kawazoe, Akihito, Yasutoshi Kuboki, Yoshito Komatsu, et al.. (2018). Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology. 36(4_suppl). 760–760. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact